

## Materials and Methods

**Plg binding-** Plg binding was measured as described previously (Das R., et al Blood, 2007). To implicate PS in Plg binding, THP-1 cells were differentiated in absence or presence of various concentrations of annexin V (Enzyme Research laboratories, IN) or protein S (BioVision). Cells were washed and incubated with 200 nM human Alexa-488-Glu-Plg, with or without 100 mM 6-aminohexanoic acid (EACA, Sigma), for 1 h at 4°C in HBSS-BSA buffer. Specific Plg binding was measured on viable cells by FACS and was defined as the component of the Alexa-488-Glu-Plg binding that was inhibited by EACA.

**Apoptosis assay-** THP-1 cells treated with IFN $\gamma$ +VD3, camptothecin or left untreated. To detect the extent of apoptosis, the cells were washed two times with PBS and stained with FITC-annexin V and propidium iodide according to the manufacturer's protocol (BD Bioscience)

**Intracellular Ca<sup>2+</sup> measurements-** THP-1 cells ( $2 \times 10^6$ ) were loaded with 2  $\mu$ M Fluo-4AM (Invitrogen) in HBSS buffer containing 1%FBS and 2.5 mM probenecid (Invitrogen) for 30 min at 22°C. Cells were washed twice with HBSS buffer, and, after 30 min at 37°C, the cells were stained with annexin V-PE (eBioscience). Intracellular levels of Ca<sup>2+</sup> and PS exposure were measured simultaneously by FACS using the FL-1 and FL-2 channels, respectively.

## Figure Legends

**Figure S1. Effect of anti-PS antibody, annexin V, protein S, amlodipine, verapamil on IFN $\gamma$ +VD3 mediated THP-1 cell differentiation.** THP-1 cells were pretreated with anti-PS (50  $\mu$ g/ml), annexin V (2  $\mu$ M), protein S (2  $\mu$ M), amlodipine (10  $\mu$ M) or verapamil (10  $\mu$ M) for 1 h and then treated with IFN $\gamma$ +VD3 for 48 h. To determine the extent of differentiation, the cells were stained with anti-CD14, anti- $\alpha_M$  Ab (clone 904) or anti- $\beta_2$  (clone IB4) and analyzed by FACS. Specific mean fluorescence intensity (MFI) values were quantified by subtracting the binding obtained with secondary antibody alone. Data are means  $\pm$  SD from triplicate experiments. IFN $\gamma$ +VD3 induced CD14,  $\alpha_M$  and  $\beta_2$  expression, and the extent of expression of these surface markers were not significantly changed by anti-PS antibody, annexin V, protein S, amlodipine or verapamil.

**Figure S2. Effect of IFN $\gamma$ +VD3 on camptothecin-induced apoptosis and of camptothecin on differentiation of THP-1 cells.** IFN $\gamma$ +VD3 (48 h) and camptothecin-treated (24 h) cells were stained for FACS using either FITC annexin V and PI (panel A) to detect apoptosis or anti-CD14 (black open), anti- $\alpha_M$  (blue open), and anti- $\beta_2$  (red open) antibodies (panel B) to detect differentiation. Data for panel A are representative of triplicate experiments. Specific mean fluorescence intensity (MFI) values for Panel B histograms are tabularized below the figure. Data are means  $\pm$  SD from triplicate histograms.

**Figure S3. Camptothecin treatment of THP-1 cells enhances intracellular Ca<sup>2+</sup> levels and PS surface expression.** THP-1 cells were either pretreated with amlodipine or verapamil for 1 h or were untreated. The cells were then induced to undergo apoptosis with camptothecin (5 μM) for 24 h. Cells were then loaded with Fluo-4AM and subsequently stained with Annexin V-PE. Intracellular Ca<sup>2+</sup> ([Ca<sup>2+</sup>]<sub>in</sub>, striated bars) and PS exposure (black bars) were measured by FACS. Data represent the mean fluorescence intensities of triplicate samples. Camptothecin treated cells show an increased [Ca<sup>2+</sup>]<sub>in</sub> and PS exposure compared to untreated control cells. The level of Ca<sup>2+</sup> is lowered in cells pretreated with amlodipine and verapamil. \*p<0.001 vs. untreated cells, #p≤ 0.001 vs. camptothecin striated bar, †p≤0.001 camptothecin black bar as analyzed by a one way ANOVA test.





Figure S1



<u>Reagent</u>	<u>Color coding</u>	<u>MFI values</u>		
		<u>Untreated</u>	<u>IFN<math>\gamma</math>+VD3</u>	<u>Camptothecin</u>
Secondary antibody	Grey filled	11.5 $\pm$ 5	13.9 $\pm$ 2	10.2 $\pm$ 4
Anti-CD14	Black open	19.2 $\pm$ 5	1230.5 $\pm$ 25	33.7 $\pm$ 6
904 (anti- $\alpha_M$ integrin)	Blue Open	32.5 $\pm$ 10	1030 $\pm$ 33	40.7 $\pm$ 8
IB4 (anti- $\beta_2$ integrin)	Red Open	358.3 $\pm$ 21	1340 $\pm$ 43	282.2 $\pm$ 16

**Figure S2**




Figure S3